SI2694043T1 - Kombinacije, obsegajoče brekspiprazol ali sol le-tega in drugo zdravilo za uporabo pri zdravljenju motnje centralnega živčnega sistema - Google Patents
Kombinacije, obsegajoče brekspiprazol ali sol le-tega in drugo zdravilo za uporabo pri zdravljenju motnje centralnega živčnega sistema Download PDFInfo
- Publication number
- SI2694043T1 SI2694043T1 SI201231192T SI201231192T SI2694043T1 SI 2694043 T1 SI2694043 T1 SI 2694043T1 SI 201231192 T SI201231192 T SI 201231192T SI 201231192 T SI201231192 T SI 201231192T SI 2694043 T1 SI2694043 T1 SI 2694043T1
- Authority
- SI
- Slovenia
- Prior art keywords
- disorder
- medicament
- disease
- treatment
- depression
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 36
- 238000011282 treatment Methods 0.000 title claims abstract 12
- 150000003839 salts Chemical class 0.000 title claims abstract 11
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 title claims abstract 3
- 229940079593 drug Drugs 0.000 title claims 14
- 229960001210 brexpiprazole Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 208000010877 cognitive disease Diseases 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 15
- 201000000980 schizophrenia Diseases 0.000 claims 15
- 208000020925 Bipolar disease Diseases 0.000 claims 9
- 208000024714 major depressive disease Diseases 0.000 claims 9
- 208000007415 Anhedonia Diseases 0.000 claims 8
- 208000027520 Somatoform disease Diseases 0.000 claims 8
- 208000015114 central nervous system disease Diseases 0.000 claims 7
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 7
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 208000020706 Autistic disease Diseases 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 6
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 6
- 230000003340 mental effect Effects 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 208000019906 panic disease Diseases 0.000 claims 5
- 208000011117 substance-related disease Diseases 0.000 claims 5
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 4
- 206010003805 Autism Diseases 0.000 claims 4
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims 4
- 229960001653 citalopram Drugs 0.000 claims 4
- 229960001623 desvenlafaxine Drugs 0.000 claims 4
- 229960002866 duloxetine Drugs 0.000 claims 4
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 4
- 229960004341 escitalopram Drugs 0.000 claims 4
- 229960002464 fluoxetine Drugs 0.000 claims 4
- 229960004038 fluvoxamine Drugs 0.000 claims 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 4
- 229960000600 milnacipran Drugs 0.000 claims 4
- 229960002296 paroxetine Drugs 0.000 claims 4
- 229960002073 sertraline Drugs 0.000 claims 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 4
- 229960004688 venlafaxine Drugs 0.000 claims 4
- 206010001605 Alcohol poisoning Diseases 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000032841 Bulimia Diseases 0.000 claims 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims 3
- 208000016134 Conjunctival disease Diseases 0.000 claims 3
- 206010012218 Delirium Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000027534 Emotional disease Diseases 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 3
- 201000001916 Hypochondriasis Diseases 0.000 claims 3
- 208000004356 Hysteria Diseases 0.000 claims 3
- 206010026749 Mania Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 206010029216 Nervousness Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010033664 Panic attack Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 206010041250 Social phobia Diseases 0.000 claims 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims 3
- 208000016620 Tourette disease Diseases 0.000 claims 3
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 208000026345 acute stress disease Diseases 0.000 claims 3
- 206010001584 alcohol abuse Diseases 0.000 claims 3
- 208000025746 alcohol use disease Diseases 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 208000012839 conversion disease Diseases 0.000 claims 3
- 208000026725 cyclothymic disease Diseases 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 208000024732 dysthymic disease Diseases 0.000 claims 3
- 201000003104 endogenous depression Diseases 0.000 claims 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 201000003995 melancholia Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000027753 pain disease Diseases 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000020685 sleep-wake disease Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- -1 4-benzo [b] thiophen-4-yl-piperazin-1-yl Chemical group 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000036626 Mental retardation Diseases 0.000 claims 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 2
- 208000030047 Sexual desire disease Diseases 0.000 claims 2
- 208000033039 Somatisation disease Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 230000003044 adaptive effect Effects 0.000 claims 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000000642 iatrogenic effect Effects 0.000 claims 2
- 230000035987 intoxication Effects 0.000 claims 2
- 231100000566 intoxication Toxicity 0.000 claims 2
- 208000016994 somatization disease Diseases 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 210000003484 anatomy Anatomy 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 229940125713 antianxiety drug Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
- KOMBINACIJE, OBSEGAJOČE BREKSPIPRAZOL ALI SOL LE-TEGA IN DRUGO ZDRAVILO ZA UPORABO PRI ZDRAVLJENJU MOTNJE CENTRALNEGA ŽIVČNEGA SISTEMA Patentni zahtevki1. Medikament, vsebujoč: (I) spojino, kije7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kvinolin-2-on, ali sol le-te in (II) najmanj eno zdravilo, izbrano iz skupine, ki jo tvorita zaviralec ponovnega privzema serotonina ter zaviralec ponovnega privzema serotonina in norepinefrina; pri čemer je omenjeni zaviralec ponovnega privzema serotonina najmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram in soli le-teh, in je omenjeni zaviralec ponovnega privzema serotonina in norepinefrina najmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo venlafaksin, duloksetin, milnacipran, desvenlafaksin in soli le-teh.
- 2. Medikament po zahtevku 1, pri čemer medikament vsebuje omenjeno spojino (I) in omenjeno zdravilo (II) v enem samem pripravku.
- 3. Medikament po zahtevku 1, pri čemer medikament obsega sestavo, vsebujočo omenjeno spojino (I), in sestavo, vsebujočo omenjeno zdravilo (II), ki sta formulirani ločeno, sestava omenjene spojine (I) pa je namenjena za uporabo v kombinaciji s sestavo omenjenega zdravila (II).
- 4. Medikament po kateremkoli od zahtevkov 1 do 3, pri katerem je omenjeno zdravilo (II) zaviralec ponovnega privzema serotonina, ki je najmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram in soli le-teh.
- 5. Medikament po kateremkoli od zahtevkov 1 do 3, pri katerem je omenjeno zdravilo (II) zaviralec ponovnega privzemanajmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo venlafaksin, duloksetin, milnacipran, desvenlafaksin in soli le-teh.
- 6. Medikament po kateremkoli od zahtevkov 1 do 5 za uporabo v profilaksi ali pri zdravljenju bolezni centralnega živčnega sistema.
- 7. Medikament za uporabo po zahtevku 6, pri katerem je bolezen centralnega živčnega sistema bolezen centralnega živčnega sistema, izbrana iz skupine, ki jo tvorijo shizofrenija, na zdravila odporna, refraktarna ali kronična shizofrenija, emocionalna motnja, psihotična motnja, motnja razpoloženja, bipolarna motnja (npr. bipolarna motnja tipa I in bipolarna motnja tipa II), manija, depresija, endogena depresija, velika depresija, melanholična in na zdravljenje odporna depresija, distimična motnja, ciklotimična motnja, anksiozna motnja (npr. panični napad, panična motnja, agorafobija, socialna fobija, obsesivno-kompulzivna motnja, post-travmatska stresna motnja, generalizirana anksiozna motnja, akutna stresna motnja), somatoformna motnja (npr. histerija, somatizacijska motnja, konverzivna motnja, bolečinska motnja, hipohondrija), ponarejena motnja, disociativna motnja, seksualna motnja (npr. seksualna disfunkcija, motnja seksualnega poželenja, motnja seksualnega vzburjenja, erektilna disfunkcija), motnja hranjenja (npr. anoreksija nervoza, bulimija nervoza), motnja spanja, prilagoditvena motnja, motnja, povezana s snovmi (npr. zloraba alkohola, alkoholna intoksikacija in toksikomanija, intoksikacija s stimulansi, narkomanija), anhedonija (npr. jatrogena anhedonija, anhedonija s psihičnim ali mentalnim vzrokom, anhedonija, povezana z depresijo, anhedonija, povezana s shizofrenijo), delirij, kognitivna motnja, kognitivna motnja, povezana z Alzheimerjevo boleznijo, Parkinsonovo boleznijo in drugimi nevrodegenerativnimi boleznimi, kognitivna motnja, ki jo povzročajo Alzheimerjeva bolezen, Parkinsonova bolezen in s tem povezane nevrodegenerativne bolezni, kognitivna motnja pri shizofreniji, kognitivna motnja, ki jo povzroča na zdravljenje odporna, refraktarna ali kronična shizofrenija, bljuvanje, gibalna bolezen, debelost, migrena, bolečina, mentalna zaostalost, avtistična motnja (avtizem), Tourettova motnja, motnja tikov, primanjkljaj pozornosti in vedenjska motnja in Dovvnov sindrom.
- 8. Farmacevtska sestava, obsegajoča medikament po kateremkoli od zahtevkov 1 do 5 in najmanj en farmakološko sprejemljiv nosilec.
- 9. Medikament, vsebujoč (I) spojino, ki je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kvinolin-2-on, ali sol le-te, za uporabo pri zdravljenju bolezni centralnega živčnega sistema pri pacientu, ki mu dajejo (II) najmanj eno zdravilo, izbrano iz skupine, ki jo tvorita zaviralec ponovnega privzema serotonina ter zaviralec ponovnega privzema serotonina in norepinefrina; pri čemer je omenjeni zaviralec ponovnega privzema serotonina zdravilo, izbrano iz skupine, ki jo tvorijo fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram in soli le-teh, in je omenjeni zaviralec ponovnega privzema serotonina in norepinefrina najmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo venlafaksin, duloksetin, milnacipran, desvenlafaksin in soli le-teh.
- 10. Medikament za uporabo po zahtevku 9, pri katerem je zdravljenje zdravljenje bolezni centralnega živčnega sistema, izbrane iz skupine, ki jo tvorijo shizofrenija, na zdravila odporna, refraktarna ali kronična shizofrenija, emocionalna motnja, psihotična motnja, motnja razpoloženja, bipolarna motnja (npr. bipolarna motnja tipa I in bipolarna motnja tipa II), manija, depresija, endogena depresija, velika depresija, melanholična in na zdravljenje odporna depresija, distimična motnja, ciklotimična motnja, anksiozna motnja (npr. panični napad, panična motnja, agorafobija, socialna fobija, obsesivno-kompulzivna motnja, post-travmatska stresna motnja, generalizirana anksiozna motnja, akutna stresna motnja), somatoformna motnja (npr. histerija, somatizacijska motnja, konverzivna motnja, bolečinska motnja, hipohondrija), ponarejena motnja, disociativna motnja, seksualna motnja (npr. seksualna disfunkcija, motnja seksualnega poželenja, motnja seksualnega vzburjenja, erektilna disfunkcija), motnja hranjenja (npr. anoreksija nervoza, bulimija nervoza), motnja spanja, prilagoditvena motnja, motnja, povezana s snovmi (npr. zloraba alkohola, alkoholna intoksikacija in toksikomanija,narkomanija), anhedonija (npr. jatrogena anhedonija, anhedonija s psihičnim ali mentalnim vzrokom, anhedonija, povezana z depresijo, anhedonija, povezana s shizofrenijo), delirij, kognitivna motnja, kognitivna motnja, povezana z Alzheimerjevo boleznijo, Parkinsonovo boleznijo in drugimi nevrodegenerativnimi boleznimi, kognitivna motnja, ki jo povzročajo Alzheimerjeva bolezen, Parkinsonova bolezen in s tem povezane nevrodegenerativne bolezni, kognitivna motnja pri shizofreniji, kognitivna motnja, ki jo povzroča na zdravljenje odporna, refraktarna ali kronična shizofrenija, bljuvanje, gibalna bolezen, debelost, migrena, bolečina, mentalna zaostalost, avtistična motnja (avtizem), Tourettova motnja, motnja tikov, primanjkljaj pozornosti in motnja hiperaktivnosti, vedenjska motnja in Dovvnov sindrom.
- 11. Medikament, vsebujoč (II) najmanj eno zdravilo, izbrano iz skupine, ki jo tvorita zaviralec ponovnega privzema serotonina ter zaviralec ponovnega privzema serotonina in norepinefrina, za uporabo pri zdravljenju bolezni centralnega živčnega sistema pri pacientu, ki mu dajejo (I) spojino, ki je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kvinolin-2-on, ali sol lete; pri čemer je zaviralec ponovnega privzema serotonina najmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo fluoksetin, citalopram, fluvoksamin, paroksetin, sertralin, escitalopram in soli le-teh, in je omenjeni zaviralec ponovnega privzema serotonina in norepinefrina najmanj eno zdravilo, izbrano iz skupine, ki jo tvorijo venlafaksin, duloksetin, milnacipran, desvenlafaksin in soli le-teh.
- 12. Medikament za uporabo po zahtevku 11, pri katerem je zdravljenje zdravljenje bolezni centralnega živčnega sistema, izbrane iz skupine, ki jo tvorijo shizofrenija, na zdravila odporna, refraktarna ali kronična shizofrenija, emocionalna motnja, psihotična motnja, motnja razpoloženja, bipolarna motnja (npr. bipolarna motnja tipa I in bipolarna motnja tipa II), manija, depresija, endogena depresija, velika depresija, melanholična in na zdravljenje odporna depresija, distimična motnja, ciklotimična motnja, anksiozna motnja (npr. panični napad,socialna fobija, obsesivno-kompulzivna motnja, post-travmatska stresna motnja, generalizirana anksiozna motnja, akutna stresna motnja), somatoformna motnja (npr. histerija, somatizacijska motnja, konverzivna motnja, bolečinska motnja, hipohondrija), ponarejena motnja, disociativna motnja, seksualna motnja (npr. seksualna disfunkcija, motnja seksualnega poželenja, motnja seksualnega vzburjenja, erektilna disfunkcija), motnja hranjenja (npr. anoreksija nervoza, bulimija nervoza), motnja spanja, prilagoditvena motnja, motnja, povezana s snovmi (npr. zloraba alkohola, alkoholna intoksikacija in toksikomanija, intoksikacija s stimulansi, narkomanija), anhedonija (npr. jatrogena anhedonija, anhedonija s psihičnim ali mentalnim vzrokom, anhedonija, povezana z depresijo, anhedonija, povezana s shizofrenijo), delirij, kognitivna motnja, kognitivna motnja, povezana z Alzheimerjevo boleznijo, Parkinsonovo boleznijo in drugimi nevrodegenerativnimi boleznimi, kognitivna motnja, ki jo povzročajo Alzheimerjeva bolezen, Parkinsonova bolezen in s tem povezane nevrodegenerativne bolezni, kognitivna motnja pri shizofreniji, kognitivna motnja, ki jo povzroča na zdravljenje odporna, refraktarna ali kronična shizofrenija, bljuvanje, gibalna bolezen, debelost, migrena, bolečina, mentalna zaostalost, avtistična motnja (avtizem), Tourettova motnja, motnja tikov, primanjkljaj pozornosti in motnja hiperaktivnosti, vedenjska motnja in Dovvnov sindrom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471911P | 2011-04-05 | 2011-04-05 | |
| US201161580540P | 2011-12-27 | 2011-12-27 | |
| EP12719460.3A EP2694043B1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| PCT/JP2012/059825 WO2012137971A1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2694043T1 true SI2694043T1 (sl) | 2018-03-30 |
Family
ID=46045045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231192T SI2694043T1 (sl) | 2011-04-05 | 2012-04-04 | Kombinacije, obsegajoče brekspiprazol ali sol le-tega in drugo zdravilo za uporabo pri zdravljenju motnje centralnega živčnega sistema |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US20140120185A1 (sl) |
| EP (4) | EP2694043B1 (sl) |
| JP (2) | JP5992924B2 (sl) |
| KR (1) | KR101890450B1 (sl) |
| CN (2) | CN103547260B (sl) |
| AR (1) | AR085840A1 (sl) |
| AU (1) | AU2012240864B2 (sl) |
| BR (1) | BR112013025420B1 (sl) |
| CA (1) | CA2832157C (sl) |
| CO (1) | CO6801769A2 (sl) |
| CY (1) | CY1120567T1 (sl) |
| DK (1) | DK2694043T3 (sl) |
| EA (1) | EA035837B1 (sl) |
| ES (1) | ES2654851T3 (sl) |
| HK (1) | HK1246159A1 (sl) |
| HR (1) | HRP20180098T1 (sl) |
| HU (1) | HUE035542T2 (sl) |
| IL (1) | IL228669B (sl) |
| JO (2) | JOP20120083B1 (sl) |
| LT (1) | LT2694043T (sl) |
| MX (2) | MX370670B (sl) |
| MY (1) | MY166936A (sl) |
| NZ (1) | NZ615591A (sl) |
| PL (1) | PL2694043T3 (sl) |
| PT (1) | PT2694043T (sl) |
| RS (1) | RS56802B1 (sl) |
| SG (2) | SG193468A1 (sl) |
| SI (1) | SI2694043T1 (sl) |
| TW (1) | TWI636784B (sl) |
| WO (1) | WO2012137971A1 (sl) |
| ZA (1) | ZA201306981B (sl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| AR088372A1 (es) * | 2011-10-19 | 2014-05-28 | Otsuka Pharma Co Ltd | Solucion para administracion oral |
| TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| TW201625252A (zh) | 2014-04-22 | 2016-07-16 | 大塚製藥股份有限公司 | 藥物 |
| US20170196846A1 (en) * | 2014-06-06 | 2017-07-13 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
| CA2936746C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| CA3019351C (en) | 2016-04-01 | 2023-09-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Regulatory device and associated method |
| US11123300B2 (en) | 2016-08-16 | 2021-09-21 | Hexal Ag | Immediate release tablet of a benzothiophene compound |
| US20200093821A1 (en) | 2016-08-16 | 2020-03-26 | Hexal Ag | Pharmaceutical Compositions of a Benzothiophene Compound |
| SG11201903770UA (en) * | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3501506B1 (en) * | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| JP2019183095A (ja) * | 2018-08-16 | 2019-10-24 | 株式会社Ｄｎｐファインケミカル | 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法 |
| JP6831354B2 (ja) * | 2018-08-16 | 2021-02-17 | 株式会社Ｄｎｐファインケミカル | 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法 |
| US20220031909A1 (en) * | 2018-10-04 | 2022-02-03 | École Polytechnique Fédérale De Lausanne (Epfl) | Cross-Linkable Polymer, Hydrogel, and Method of Preparation Thereof |
| EP3870178A4 (en) * | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | CRYSTALLINE FORMS OF MNK INHIBITORS |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| CN113322299A (zh) * | 2021-05-28 | 2021-08-31 | 南昌大学 | 一种抑郁症和药物成瘾疾病的药物靶点识别方法 |
| US20240009181A1 (en) * | 2022-07-08 | 2024-01-11 | Jason Eric Schiffman | Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same |
| FR3142667A1 (fr) * | 2022-12-01 | 2024-06-07 | Capsum | Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| TW587938B (en) * | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US20040176466A1 (en) * | 2001-08-08 | 2004-09-09 | Allen Albert John | Combination therapy for the treatment of neurological disorders |
| CN1989968B (zh) * | 2002-12-27 | 2011-05-11 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
| WO2006004719A2 (en) * | 2004-06-25 | 2006-01-12 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| CN101646432A (zh) * | 2006-10-27 | 2010-02-10 | 詹森药业有限公司 | 治疗破坏性行为障碍的方法 |
| JP2008189616A (ja) * | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | 注意欠陥多動性障害の治療薬 |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
-
2012
- 2012-04-03 AR ARP120101135A patent/AR085840A1/es unknown
- 2012-04-03 TW TW101111875A patent/TWI636784B/zh active
- 2012-04-03 JO JOP/2012/0083A patent/JOP20120083B1/ar active
- 2012-04-04 US US14/009,436 patent/US20140120185A1/en not_active Abandoned
- 2012-04-04 MY MYPI2013701740A patent/MY166936A/en unknown
- 2012-04-04 ES ES12719460.3T patent/ES2654851T3/es active Active
- 2012-04-04 MX MX2013010796A patent/MX370670B/es active IP Right Grant
- 2012-04-04 BR BR112013025420-3A patent/BR112013025420B1/pt active IP Right Grant
- 2012-04-04 PT PT127194603T patent/PT2694043T/pt unknown
- 2012-04-04 KR KR1020137029250A patent/KR101890450B1/ko active IP Right Grant
- 2012-04-04 DK DK12719460.3T patent/DK2694043T3/en active
- 2012-04-04 CA CA2832157A patent/CA2832157C/en active Active
- 2012-04-04 LT LTEP12719460.3T patent/LT2694043T/lt unknown
- 2012-04-04 NZ NZ615591A patent/NZ615591A/en unknown
- 2012-04-04 SG SG2013069273A patent/SG193468A1/en unknown
- 2012-04-04 AU AU2012240864A patent/AU2012240864B2/en active Active
- 2012-04-04 EP EP12719460.3A patent/EP2694043B1/en not_active Revoked
- 2012-04-04 SI SI201231192T patent/SI2694043T1/sl unknown
- 2012-04-04 WO PCT/JP2012/059825 patent/WO2012137971A1/en active Application Filing
- 2012-04-04 SG SG10201602326RA patent/SG10201602326RA/en unknown
- 2012-04-04 EA EA201391450A patent/EA035837B1/ru not_active IP Right Cessation
- 2012-04-04 EP EP17198877.7A patent/EP3299018A1/en not_active Withdrawn
- 2012-04-04 EP EP22155365.4A patent/EP4023223A1/en active Pending
- 2012-04-04 CN CN201280017329.8A patent/CN103547260B/zh active Active
- 2012-04-04 EP EP19205895.6A patent/EP3626243A1/en not_active Withdrawn
- 2012-04-04 RS RS20180064A patent/RS56802B1/sr unknown
- 2012-04-04 HU HUE12719460A patent/HUE035542T2/hu unknown
- 2012-04-04 JP JP2013546481A patent/JP5992924B2/ja active Active
- 2012-04-04 CN CN201810096214.1A patent/CN108042808B/zh active Active
- 2012-04-04 PL PL12719460T patent/PL2694043T3/pl unknown
-
2013
- 2013-09-17 ZA ZA2013/06981A patent/ZA201306981B/en unknown
- 2013-09-20 MX MX2019015237A patent/MX2019015237A/es unknown
- 2013-10-01 IL IL228669A patent/IL228669B/en active IP Right Grant
- 2013-11-05 CO CO13261085A patent/CO6801769A2/es not_active Application Discontinuation
-
2014
- 2014-05-09 HK HK18105601.0A patent/HK1246159A1/zh unknown
-
2016
- 2016-08-18 JP JP2016160872A patent/JP2017031155A/ja active Pending
- 2016-12-21 US US15/386,289 patent/US20170100395A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,102 patent/US20180042923A1/en not_active Abandoned
-
2018
- 2018-01-17 CY CY20181100057T patent/CY1120567T1/el unknown
- 2018-01-18 HR HRP20180098TT patent/HRP20180098T1/hr unknown
- 2018-07-20 US US16/041,246 patent/US20180325894A1/en not_active Abandoned
-
2021
- 2021-02-25 JO JOP/2021/0035A patent/JOP20210035A1/ar unknown
- 2021-03-10 US US17/197,725 patent/US20220000861A1/en not_active Abandoned
-
2023
- 2023-08-25 US US18/455,757 patent/US20240156811A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2694043T1 (sl) | Kombinacije, obsegajoče brekspiprazol ali sol le-tega in drugo zdravilo za uporabo pri zdravljenju motnje centralnega živčnega sistema | |
| NZ630260A (en) | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same | |
| BR112013027479A8 (pt) | Uso de um composto compreendendo um oligonucleotídeo modificado dirigido a apociii | |
| BR112015021336A2 (pt) | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso | |
| JP2002523491A5 (sl) | ||
| CU20150180A7 (es) | Piridin-2 que contienen il-4-derivados sustituidos de 1-diazino fenilo útiles como ligandos de dopamina | |
| RU2011113443A (ru) | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов | |
| AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
| JP2015514677A5 (sl) | ||
| BRPI0815748B8 (pt) | uso de iota-carragenina em uma quantidade antiviral eficaz | |
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| WO2009013212A3 (en) | Dual modulators of 5-ht2a and d3 receptors | |
| MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| EA201890402A1 (ru) | 5-htрецепторные агонисты и композиции и способы применения | |
| FI3908570T3 (fi) | Ketamiinipamoaatti ja sen käyttö | |
| BR112018013955A2 (pt) | ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina | |
| JP2022180531A5 (sl) | ||
| Bakir et al. | Histopathologic results of long-term sildenafil administration on rat inner ear | |
| MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| EP1694353A2 (en) | Composition and methods for modulating cns activity | |
| WO2010026110A3 (en) | 6-substituted benzoxazines as 5-ht-5a receptor antagonists | |
| BRPI0909824A2 (pt) | 2-aminoquinolinas |